The story
Founded by Wilson Greatbatch in 1970.1
ITGR on NYSE
Integer
American medical technology company based in Clarence, founded in 19701
In its 2026 annual report the company says: “Integer is now a pure-play medical technology company focused on Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets.”6 It was founded by Wilson Greatbatch.1 Its shares trade on NYSE under the symbol ITGR.1
$126.72 up 0.12 (0.09%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 21, 2026.
Overview
1970Founded1
Compare with LivaNova, CONMED Corporation or TransMedics Group, Inc., or pick any stock.
- TickerITGR on NYSE1
- IndustryElectromedical & Electrotherapeutic Apparatus1
- HeadquartersFrisco1
- Websitewww.integer.net
- Incorporated inDE4
- Business address5830 Granite Parkway., Suite 1150, Plano, Tx 750244
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
Integer Holdings Corporation, headquartered in Plano, Texas, is one of the world’s largest medical device contract development and manufacturing organizations (“CDMOs”), serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. Our brands include Greatbatch Medical ® and Lake Region Medical ® . Our primary customers include large, multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. When used in this report, the terms “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
27.0%Gross margin7
11.9%Operating margin7
5.5%Net margin7
8.0%Revenue growth, 20257
5.9%Return on equity7
0.68×Debt to equity7
$105.1MFree cash flow7
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Cardio And Vascular brought in 60% of the revenue Integer broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cardio And Vascular | $836.3M | $949.6M | $1.1B |
| Cardiac Rhythm Management & Neuromodulation | $612.9M | $660.6M | $668.8M |
| Other Markets | $106.4M | $106.4M | $77.8M |
Regions
United States brought in 53% of the revenue Integer broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $872.9M | $938.7M | $979.8M |
| Rest Of World | $383.7M | $431.8M | $469.9M |
| CR | $108.4M | $124.7M | $173.5M |
| PR | $121.5M | $137.1M | $131.3M |
| I E | $69.1M | $84.4M | $99.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue73¢$1.4B
- Selling, general and admin11¢$211.7M
- Other costs9¢$163.3M
- Income tax1¢$22.6M
- Profit6¢$102.8M
Out of $1.9B in revenue.7
Where each dollar of operating cash went, fiscal 2025
- Capital spending46¢$91.0M
- Share buybacks25¢$50.0M
- Kept or used elsewhere28¢$55.1M
Out of $196.1M of cash from operations.7
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Sales | $1.9B | $1.7B | $1.6B |
| Cost of sales | $1.4B | $1.3B | $1.1B |
| Gross profit | $500.4M | $459.0M | $409.9M |
| Selling, general and administrative | $211.7M | $185.2M | $173.2M |
| Research, development and engineering | $49.5M | $53.4M | $62.0M |
| Restructuring and other charges | $17.9M | $12.1M | $11.4M |
| Total operating expenses | $279.1M | $250.8M | $246.6M |
| Operating income | $221.3M | $208.2M | $163.3M |
| Interest expense | $43.2M | $56.4M | $51.3M |
| (Gain) loss on equity investments, net | -$550.0K | $780.0K | $5.7M |
| Other loss, net | $53.2M | $3.5M | $975.0K |
| Income from continuing operations before income taxes | $125.4M | $147.6M | $105.4M |
| Provision for income taxes | $22.6M | $26.5M | $16.2M |
| Income from continuing operations | $102.8M | $121.1M | $89.1M |
| Income (loss) from discontinued operations, net of tax | -$22.0K | -$1.2M | $1.5M |
| Net income | $102.8M | $119.9M | $90.7M |
| Income from continuing operations (in dollars per share) | $3 | $4 | $3 |
| Income from discontinued operations (in dollars per share) | $0 | -$0 | $0 |
| Basic earnings per share (in dollars per share) | $2.96 | $3.57 | $2.72 |
| Income from continuing operations (in dollars per share) | $3 | $3 | $3 |
| Income (loss) from discontinued operations (in dollars per share) | $0 | -$0 | $0 |
| Diluted earnings per share (in dollars per share) | $2.89 | $3.36 | $2.69 |
| Basic (in shares) | 34.7M shares | 33.6M shares | 33.3M shares |
| Diluted (in shares) | 35.6M shares | 35.6M shares | 33.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $17.2M | $46.5M | ||
| Accounts receivable, net of provision for credit losses of $0.6 million and $0.3 million, respectively | $346.1M | $245.3M | ||
| Inventories | $253.7M | $247.1M | ||
| Contract assets | $112.5M | $103.8M | ||
| Prepaid expenses and other current assets | $40.6M | $28.4M | ||
| Total current assets | $770.1M | $671.1M | ||
| Property, plant and equipment, net | $536.4M | $465.8M | ||
| Goodwill | $1.1B | $1.0B | $994.0M | |
| Other intangible assets, net | $825.4M | $778.3M | ||
| Deferred income taxes | $9.0M | $8.3M | ||
| Operating lease assets | $98.4M | $86.1M | ||
| Financing lease assets | $37.1M | $27.7M | ||
| Other long-term assets | $23.2M | $23.0M | ||
| Total assets | $3.4B | $3.1B | ||
| Current portion of long-term debt | $0 | $10.0M | ||
| Accounts payable | $113.1M | $101.5M | ||
| Operating lease liabilities | $9.1M | $7.4M | ||
| Accrued expenses and other current liabilities | $109.8M | $108.3M | ||
| Total current liabilities | $232.0M | $227.2M | ||
| Long-term debt | $1.2B | $980.2M | ||
| Deferred income taxes | $116.3M | $124.6M | ||
| Operating lease liabilities | $81.9M | $77.7M | ||
| Financing lease liabilities | $28.6M | $23.8M | ||
| Other long-term liabilities | $19.9M | $25.4M | ||
| Total liabilities | $1.7B | $1.5B | ||
| Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding | $0 | $0 | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 35,481,805 and 33,546,262 shares issued, respectively, and 34,346,450 and 33,546,256 outstanding, respectively | $35.0K | $34.0K | ||
| Additional paid-in capital | $771.2M | $742.0M | ||
| Treasury stock, at cost, 1,135,355 shares and 6 shares, respectively | -$76.9M | $0 | ||
| Retained earnings | $994.1M | $891.2M | ||
| Accumulated other comprehensive income (loss) | $58.2M | -$14.0M | ||
| Total stockholders equity | $1.7B | $1.6B | $1.5B | $1.4B |
| Total liabilities and stockholders equity | $3.4B | $3.1B | ||
| Allowance for doubtful accounts | $600.0K | $300.0K | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued (in shares) | 35.5M shares | 33.5M shares | ||
| Common stock, shares outstanding (in shares) | 34.3M shares | 33.5M shares | ||
| Treasury stock, shares (in shares) | 1.1M shares | 6 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $17.2M | $46.5M | ||
| Accounts receivable, net of provision for credit losses of $0.6 million and $0.3 million, respectively | $346.1M | $245.3M | ||
| Inventories | $253.7M | $247.1M | ||
| Contract assets | $112.5M | $103.8M | ||
| Prepaid expenses and other current assets | $40.6M | $28.4M | ||
| Total current assets | $770.1M | $671.1M | ||
| Property, plant and equipment, net | $536.4M | $465.8M | ||
| Goodwill | $1.1B | $1.0B | $994.0M | |
| Other intangible assets, net | $825.4M | $778.3M | ||
| Deferred income taxes | $9.0M | $8.3M | ||
| Operating lease assets | $98.4M | $86.1M | ||
| Financing lease assets | $37.1M | $27.7M | ||
| Other long-term assets | $23.2M | $23.0M | ||
| Total assets | $3.4B | $3.1B | ||
| Current portion of long-term debt | $0 | $10.0M | ||
| Accounts payable | $113.1M | $101.5M | ||
| Operating lease liabilities | $9.1M | $7.4M | ||
| Accrued expenses and other current liabilities | $109.8M | $108.3M | ||
| Total current liabilities | $232.0M | $227.2M | ||
| Long-term debt | $1.2B | $980.2M | ||
| Deferred income taxes | $116.3M | $124.6M | ||
| Operating lease liabilities | $81.9M | $77.7M | ||
| Financing lease liabilities | $28.6M | $23.8M | ||
| Other long-term liabilities | $19.9M | $25.4M | ||
| Total liabilities | $1.7B | $1.5B | ||
| Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding | $0 | $0 | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 35,481,805 and 33,546,262 shares issued, respectively, and 34,346,450 and 33,546,256 outstanding, respectively | $35.0K | $34.0K | ||
| Additional paid-in capital | $771.2M | $742.0M | ||
| Treasury stock, at cost, 1,135,355 shares and 6 shares, respectively | -$76.9M | $0 | ||
| Retained earnings | $994.1M | $891.2M | ||
| Accumulated other comprehensive income (loss) | $58.2M | -$14.0M | ||
| Total stockholders equity | $1.7B | $1.6B | $1.5B | $1.4B |
| Total liabilities and stockholders equity | $3.4B | $3.1B | ||
| Allowance for doubtful accounts | $600.0K | $300.0K | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued (in shares) | 35.5M shares | 33.5M shares | ||
| Common stock, shares outstanding (in shares) | 34.3M shares | 33.5M shares | ||
| Treasury stock, shares (in shares) | 1.1M shares | 6 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $102.8M | $119.9M | $90.7M |
| Depreciation and amortization | $130.7M | $111.0M | $98.8M |
| Debt related charges included in interest expense | $6.9M | $4.1M | $8.1M |
| Debt conversion inducement expense | $46.7M | $0 | $0 |
| Inventory step-up amortization | $0 | $1.1M | $590.0K |
| Stock-based compensation | $23.2M | $24.8M | $23.3M |
| Non-cash lease expense | $10.2M | $9.1M | $11.2M |
| Non-cash (gain) loss on equity investments | -$550.0K | $780.0K | $5.7M |
| Contingent consideration fair value adjustment | -$2.3M | -$3.5M | -$736.0K |
| Other non-cash losses | $1.7M | $7.0M | $4.4M |
| Deferred income taxes | -$2.7M | -$14.1M | -$9.5M |
| Gain on sale of discontinued operations | -$46.0K | -$177.0K | $0 |
| Accounts receivable | -$82.4M | -$6.5M | -$7.4M |
| Inventories | -$2.6M | -$18.1M | -$30.2M |
| Contract assets | -$7.3M | -$18.4M | -$13.6M |
| Prepaid expenses and other assets | -$2.5M | -$229.0K | -$930.0K |
| Accounts payable | -$566.0K | -$16.6M | -$520.0K |
| Accrued expenses and other liabilities | -$20.3M | $4.5M | $7.9M |
| Income taxes payable | -$4.9M | $811.0K | -$7.5M |
| Net cash provided by operating activities | $196.1M | $205.2M | $180.2M |
| Acquisition of property, plant and equipment | -$91.0M | -$105.4M | -$119.9M |
| Acquisitions, net of cash acquired | -$178.9M | -$138.5M | -$43.6M |
| Proceeds (settlement of working capital) from sale of discontinued operations, net | -$950.0K | $48.7M | $0 |
| Other investing activities | $123.0K | -$211.0K | $173.0K |
| Net cash used in investing activities | -$270.7M | -$195.4M | -$163.4M |
| Principal payments of long-term debt | -$667.7M | -$6.0K | -$415.9M |
| Proceeds from issuance of convertible notes, net of discount | $977.5M | $0 | $486.2M |
| Proceeds from revolving credit facility | $307.0M | $274.5M | $383.1M |
| Payments of revolving credit facility | -$433.0M | -$247.5M | -$424.8M |
| Purchase of capped calls | -$71.0M | $0 | -$35.0M |
| Payment of debt issuance costs | -$1.4M | -$2.1M | -$2.2M |
| Repurchases of common stock | -$50.0M | $0 | $0 |
| Proceeds from the exercise of stock options | $3.6M | $742.0K | $2.3M |
| Tax withholdings related to net share settlements of restricted stock units | -$16.9M | -$10.9M | -$3.1M |
| Payment of contingent consideration | $0 | $0 | -$7.7M |
| Principal payments on finance leases | -$5.9M | -$10.7M | -$1.2M |
| Other financing activities | $1.4M | $9.3M | $190.0K |
| Net cash provided by (used in) financing activities | $43.6M | $13.3M | -$18.0M |
| Effect of foreign currency exchange rates on cash and cash equivalents | $1.6M | -$243.0K | $570.0K |
| Net increase (decrease) in cash and cash equivalents | -$29.4M | $22.9M | -$598.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Integer sits at the top of its group. 32 entities, 10 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Integer
- Tarheel Investors III L.P. Filed SCHEDULE 13D on Integer, latest Oct 13, 2026
- Nomura Holdings Filed SCHEDULE 13G on Integer, latest Aug 14, 2026
- Invesco Filed SCHEDULE 13G on Integer, latest May 6, 2026
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Integer, latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on Integer, latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Integer, latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on Integer, latest Jul 17, 2025 (5 filings since Jan 28, 2022)
- DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G/A on Integer, latest Apr 15, 2025 (5 filings since Feb 8, 2022)
- FRANKLIN MUTUAL ADVISERS LLC Filed SC 13G/A on Integer, latest Jan 30, 2024 (2 filings since Jan 31, 2023)
- Integer Frisco
- Accellent LLC Subsidiary · Colorado, United States
- Aran Biomedical Teoranta Subsidiary · Ireland
- Brivant Limited, d/b/a Lake Region Medical Subsidiary · Ireland
- Centro de Construcción de Cardioestimuladores del Uruguay SA Subsidiary · Uruguay
- Connemara Biomedical Holdings Teo. Subsidiary · Ireland
- CPE 1, LLC Subsidiary · Delaware, United States
- Greatbatch LLC Subsidiary · Delaware, United States
- Greatbatch Ltd., d/b/a Greatbatch Medical Subsidiary · New York, United States
- Greatbatch MCSO, S. de R.L. de C.V Subsidiary · Mexico
- Greatbatch Medical SA Subsidiary · Switzerland
- Greatbatch Medical, S. de R.L. de C.V. Subsidiary · Mexico
- Greatbatch Netherlands B.V. Subsidiary · Netherlands
- Integer EBDO SA Subsidiary · Switzerland
- Integer Hydrophilic Technologies LLC Subsidiary · Delaware, United States
- Integer N2 Surface Technologies LLC Subsidiary · Delaware, United States
- Integer Precision Technologies, LLC Subsidiary · Delaware, United States
- Integer SMI Ltd. Subsidiary · Israel
- Integer VSi Technologies, LLC Subsidiary · Delaware, United States
- Lake (Shanghai) Medical Device Trading Co., Ltd. Subsidiary · China
- Lake Region Manufacturing, Inc., d/b/a Lake Region Medical Subsidiary · Minnesota, United States
- Lake Region Medical Holdings Limited Subsidiary · Ireland
- Lake Region Medical Limited Subsidiary · Ireland
- Lake Region Medical, Inc., d/b/a Lake Region Medical Subsidiary · Maryland, United States
- Oscor Caribe LLC Subsidiary · Florida, United States
- Oscor Europe GmbH Subsidiary · Germany
- and 6 more
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Integer reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.1B7 Dec 31, 2025 | $968.0M7 Dec 31, 2024 | +14.2% |
| Accumulated depreciation | $569.0M7 Dec 31, 2025 | $502.2M7 Dec 31, 2024 | +13.3% |
| Property and equipment, net | $536.4M7 Dec 31, 2025 | $465.8M7 Dec 31, 2024 | +15.2% |
| Finance-lease assets | $37.1M7 Dec 31, 2025 | $27.7M7 Dec 31, 2024 | +34.0% |
| Operating-lease assets (leased space) | $98.4M7 Dec 31, 2025 | $86.1M7 Dec 31, 2024 | +14.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $17.2M7 Dec 31, 2025 | $46.5M7 Dec 31, 2024 | −63.1% |
| Stakes in other companies (equity method) | $7.9M7 Dec 31, 2025 | $7.4M7 Dec 31, 2024 | +6.4% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $1.1B7 Dec 31, 2025 | $1.0B7 Dec 31, 2024 | +9.2% |
| Intangible assets, net (excluding goodwill) | $825.4M7 Dec 31, 2025 | $778.3M7 Dec 31, 2024 | +6.1% |
| Finite-lived intangibles, gross | $1.3B7 Dec 31, 2025 | $1.2B7 Dec 31, 2024 | +10.4% |
| Accumulated amortization | $571.9M7 Dec 31, 2025 | $495.9M7 Dec 31, 2024 | +15.3% |
| Finite-lived intangibles, net | $735.1M7 Dec 31, 2025 | $688.0M7 Dec 31, 2024 | +6.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $253.7M7 Dec 31, 2025 | $247.1M7 Dec 31, 2024 | +2.7% |
| Raw materials | $94.1M7 Dec 31, 2025 | $104.6M7 Dec 31, 2024 | −10.0% |
| Work in process | $143.5M7 Dec 31, 2025 | $126.8M7 Dec 31, 2024 | +13.1% |
| Finished goods | $16.1M7 Dec 31, 2025 | $15.7M7 Dec 31, 2024 | +2.8% |
Properties, in its own words
Our principal executive office and headquarters is located in Plano, Texas, in a leased facility. As of December 31, 2025, we operated 21 facilities in the U.S., 3 in Mexico, 3 in Ireland, and one facility each in the Dominican Republic, Uruguay, Malaysia, China, Costa Rica and Switzerland. Of these facilities, 26 were leased and 7 were owned. We occupy approximately 2.3 million square feet of manufacturing and RD&E space worldwide, the majority of which is located in the U.S. Mexico and Ireland. We believe the facilities we operate and their equipment are effectively utilized, well maintained, generally are in good condition, and will be able to accommodate our capacity needs to meet current levels of demand. We continuously review our anticipated requirements for facilities and, on the basis of that review, may from time to time acquire additional facilities or expand or dispose of existing facilities.
Item 2 of the 10-K filed Feb 23, 2026.6
Leadership
Who has led Integer, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
19801990200020102020
- FounderWilson Greatbatch1
- Chief executive officerPayman Khales Oct 27, 2025 to now15
- Chief executive officerJoseph W. Dziedzic Mar 29, 2017 to Oct 27, 202516
- Chief executive officerEdward F. Voboril Jan 25, 2006 to Aug 3, 200617
- Chief executive officerThomas J. Hook Aug 9, 2006 to Mar 14, 201718
- ChairEdward F. Voboril Jan 25, 2006 to Aug 3, 200617
- PresidentAndrew Senn Feb 24, 2026 to now19
- PresidentCarter Houghton May 13, 2019 to Jan 4, 202320
- PresidentPayman Khales Feb 23, 2018 to May 13, 201921
- PresidentJoseph W. Dziedzic Mar 29, 2017 to Feb 23, 201816
- PresidentJennifer M. Bolt Nov 5, 2015 to Apr 3, 201922
- PresidentJeremy Friedman Nov 5, 2015 to Nov 5, 201523
- PresidentJose Antonio Gonzalez Nov 5, 2015 to Mar 4, 201924
- PresidentMauricio Arellano Jan 4, 2011 to Mar 5, 201325
- PresidentThomas J. Hook Aug 9, 2006 to Mar 14, 201718
- Chief financial officerDiron Smith May 10, 2023 to Sep 6, 202326
- Chief financial officerJeremy Friedman Aug 8, 2018 to Aug 20, 201827
- Chief financial officerGary J. Haire May 1, 2017 to May 17, 201828
- Chief financial officerMichael Dinkins May 9, 2012 to Jan 25, 201629
- Chief financial officerThomas J. Mazza Feb 15, 2006 to Mar 6, 201230
- Chief operating officerJeremy Friedman Oct 19, 2016 to Jan 2, 201931
- Chief operating officerThomas J. Hook Feb 15, 2006 to Feb 15, 200632
Board members and other officers (59)
- US - EVP, OperationsMilo Stephen Metcalf Ii. Jul 10, 2026 to now33
- SVP, Gen Counsel & SecretaryLindsay K. Blackwood Mar 26, 2025 to now34
- SVP, Investor RelationsSanjiv Arora Apr 9, 2025 to now35
- EVP, Qlty & Regulatory AffairsTerence Carr May 15, 2025 to now36
- EVP, Chief Financial OfficerDiron Smith Jan 23, 2024 to now37
- SVP, Quality & Regulatory AffaMargaret Carthy Jan 18, 2022 to Feb 25, 202538
- SVP, Gen Counsel & SecretaryMcAlister C. Marshall Ii. Jan 21, 2022 to Feb 25, 202539
- SVP, Strategy and Business DevAndrew Senn Mar 15, 2022 to now40
- SVP, Global OperationsJennifer M. Bolt Jan 7, 2020 to Jan 24, 202341
- SVP Strategy,Corp Dev., IRAnthony W. Borowicz Mar 1, 2019 to Jan 4, 202242
- Chief Human Resources OfficerKirk K. Thor Jan 3, 2018 to now43
- VP, Corporate ControllerTommy P. Thomas Feb 5, 2018 to now44
- EVP, Chief Financial OfficerJason K. Garland Oct 3, 2018 to Jan 24, 202345
- EVP, Quality & Regulatory AffaJoseph F. Flanagan May 31, 2017 to Jan 4, 202246
- Pres., Advanced Surgical, OrthDeclan Smyth Nov 5, 2015 to May 17, 201847
- Chief Human Resource OfficerKristin Trecker Nov 6, 2015 to Feb 8, 201748
- EVP, Global Sales & Mktg, QiGThomas Kelley Hickman Aug 7, 2014 to Jan 7, 201549
- VP, Corporate ControllerThomas J. Mazza Jan 2, 2013 to Jan 5, 201850
- EVP, Global Sales & MarketingAndrew P. Holman Jun 11, 2013 to Jan 25, 201651
- SVP, Chief Technology OfficerGeorge M. Cintra Jun 11, 2013 to Jan 21, 201552
- Chief Technology OfficerDaniel Robert Kaiser Mar 8, 2012 to Jan 3, 201353
- Sr. VP Human ResourcesMichelle Graham Dec 13, 2010 to Aug 11, 201454
- VP EuropeJohn Ayliffe Mar 4, 2008 to Sep 12, 200855
- Sr. VP OrthopedicsPatrick Berdoz Mar 4, 2008 to Mar 5, 200856
- Vice PresidentTimothy G. McEvoy Feb 7, 2007 to Jan 2, 201957
- Vice President, Human ResourceBarbara M. Davis May 24, 2007 to Jan 5, 201058
- VP, Sales and MarketingRichard M. Farrell Dec 12, 2007 to Jan 5, 201059
- Sr.VP, Administration and SecrLarry T. Deangelo Feb 15, 2006 to Jan 3, 200760
- Corporate ControllerMarco Benedetti Feb 15, 2006 to Mar 6, 201261
- VP, Medical Solutions GroupMauricio Arellano Nov 13, 2006 to Jan 19, 201662
- VP, Medical Power GroupSusan H. Campbell Nov 13, 2006 to Mar 12, 201063
- VP, Commercial PowerSusan M. Bratton Nov 13, 2006 to Jun 12, 201364
- Board memberAaron Kapito Mar 25, 2026 to now65
- Board memberMichael J. Coyle Jul 14, 2025 to now66
- Board memberPayman Khales Oct 27, 2025 to now15
- Board memberAlvin Tyrone Jeffers Feb 2, 2021 to now67
- Board memberCheryl C. Capps Feb 2, 2021 to now68
- Board memberSheila Antrum Feb 2, 2021 to now69
- Board memberJames F. Hinrichs Feb 12, 2018 to now70
- Board memberMarcia A. Dall May 4, 2015 to May 7, 201571
- Board memberFilippo Passerini Jul 7, 2015 to now72
- Board memberJean M. Hobby Jul 7, 2015 to now73
- Board memberMartin C. Maxwell Jul 7, 2015 to now74
- Board memberJoseph W. Dziedzic Mar 1, 2013 to now75
- Board memberRudy A. Mazzocchi Dec 6, 2012 to Jan 6, 201476
- Board memberAnthony P. Bihl Iii. Oct 17, 2011 to Jan 5, 201677
- Board memberHelena S. Wisniewski Mar 4, 2008 to Jan 4, 201278
- Board memberMichael Dinkins Nov 7, 2008 to Jan 4, 201279
- Board memberKevin C. Melia Aug 8, 2007 to Jan 6, 201480
- Board memberJohn P. Wareham Jan 4, 2006 to Jan 5, 201081
- Board memberPamela G. Bailey Jan 4, 2006 to now82
- Board memberPeter H. Soderberg Jan 4, 2006 to May 22, 202083
- Board memberWilliam B. Summers Jr. Jan 4, 2006 to Jun 14, 202484
- Board memberBill R. Sanford Feb 15, 2006 to May 19, 202285
- Board memberJoseph A. Miller Feb 15, 2006 to Jan 5, 201686
- Board memberThomas S. Summer Feb 15, 2006 to May 29, 200887
- Board memberEdward F. Voboril Aug 9, 2006 to Jan 2, 200888
- Board memberThomas J. Hook Aug 9, 2006 to Mar 14, 201718
- General counselElizabeth Giddens Aug 19, 2019 to Aug 17, 202189
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Accellent LLC Colorado5
- Aran Biomedical Teoranta Ireland5
- Brivant Limited, d/b/a Lake Region Medical Ireland5
- CPE 1, LLC Delaware5
- Centro de Construcción de Cardioestimuladores del Uruguay SA Uruguay5
- Connemara Biomedical Holdings Teo. Ireland5
- Greatbatch LLC Delaware5
- Greatbatch Ltd., d/b/a Greatbatch Medical New York5
- Greatbatch MCSO, S. de R.L. de C.V Mexico5
- Greatbatch Medical SA Switzerland5
- Greatbatch Medical, S. de R.L. de C.V. Mexico5
- Greatbatch Netherlands B.V. Netherlands5
- Integer EBDO SA Switzerland5
- Integer Hydrophilic Technologies LLC Delaware5
- Integer N2 Surface Technologies LLC Delaware5
- Integer Precision Technologies, LLC Delaware5
- Integer SMI Ltd. Israel5
- Integer VSi Technologies, LLC Delaware5
- Lake (Shanghai) Medical Device Trading Co., Ltd. China5
- Lake Region Manufacturing, Inc., d/b/a Lake Region Medical Minnesota5
- Lake Region Medical Holdings Limited Ireland5
- Lake Region Medical Limited Ireland5
- Lake Region Medical Sdn. Bhd. Malaysia5
- Lake Region Medical, Inc., d/b/a Lake Region Medical Maryland5
All 32 listed subsidiaries
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Oct 14, 20268-K Other events90
- Oct 2, 20268-K Other events91
- Sep 30, 20268-K Other events92
- Aug 4, 20268-K Entered a material agreement; Bylaws or fiscal year changed93
- Aug 3, 20268-K Results of operations94
- Aug 3, 20268-K Regulation FD disclosure95
- Jun 26, 20268-K Executive or director change96
- May 22, 20268-K Executive or director change; Shareholder vote97
- Apr 30, 20268-K Results of operations; Regulation FD disclosure98
- Mar 12, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure99
- Feb 19, 20268-K Results of operations; Regulation FD disclosure100
- Nov 4, 20258-K Other events101
- Oct 27, 2025New chief executive Payman Khales becomes CEO15
- Mar 29, 2017New chief executive Joseph W. Dziedzic becomes CEO16
- Jul 1, 2016Renamed Name changed to Integer Holdings Corporation1
- Aug 9, 2006New chief executive Thomas J. Hook becomes CEO18
- Jan 25, 2006New chief executive Edward F. Voboril becomes CEO17
- 2005Renamed Name changed to Greatbatch, Inc.1
- 2000Went public Listed on NYSE1
- 1970Founded Founded1
Calendar
Coming up
- Oct 22, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $1.79 a share, on Oct 23, 2025.102
When it reported results
- Aug 3, 2026Reported quarterly or annual results94
- Apr 30, 2026Reported quarterly or annual results98
- Feb 19, 2026Reported quarterly or annual results100
- Oct 23, 2025Reported quarterly or annual results103
- Jul 24, 2025Reported quarterly or annual results104
- Apr 24, 2025Reported quarterly or annual results105
- Feb 20, 2025Reported quarterly or annual results106
- Oct 24, 2024Reported quarterly or annual results107
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
380 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 60 major events, 227 insider forms, 21 large holders, 51 other. The latest 20:
- Oct 15, 20263 EDGAR
- Oct 14, 20268-K EDGAR
- Oct 13, 2026SCHEDULE 13D EDGAR
- Oct 2, 20268-K EDGAR
- Sep 30, 20268-K EDGAR
- Sep 16, 20264 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 14, 2026DEFM14A EDGAR
- Sep 11, 2026144 EDGAR
- Sep 10, 20264 EDGAR
- Sep 8, 2026144 EDGAR
- Sep 3, 2026PREM14A EDGAR
- Aug 19, 2026DEFA14A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 2026DEFA14A EDGAR
- Aug 4, 20268-K EDGAR
- Aug 3, 20268-K EDGAR
- Aug 3, 2026DEFA14A EDGAR
- Aug 3, 2026DEFA14A EDGAR
The 380 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
31 open-market trades by officers, directors and large owners since October 2021: 6 buys and 25 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Thor Kirk KChief Human Resources Officer | Sale | 11,767 | $126.23 | $1.5M | Form 4 |
| Sep 14, 2026 | Thor Kirk KChief Human Resources Officer | Sale | 19,773 | $126.25 | $2.5M | Form 4 |
| Sep 8, 2026 | Senn AndrewPresident, Growth & Innovation | Sale | 9,408 | $126.30 | $1.2M | Form 4 |
| Mar 13, 2026 | Thomas Tommy PVP, Corporate Controller | Sale | 825 | $85.00 | $70.1K | Form 4 |
| Nov 12, 2025 | Harris John APresident, Glob Ops & Manu Tec | Buy | 1,650 | $70.00 | $115.5K | Form 4 |
| Nov 11, 2025 | Thomas Tommy PVP, Corporate Controller | Sale | 884 | $70.15 | $62.0K | Form 4 |
| Nov 7, 2025 | Smith DironEVP, Chief Financial Officer | Buy | 1,116 | $67.19 | $75.0K | Form 4 |
| Nov 6, 2025 | Capps Cheryl CDirector | Buy | 1,600 | $66.70 | $106.7K | Form 4 |
| Oct 30, 2025 | Khales PaymanPresident & CEO | Buy | 3,127 | $64.94 | $203.1K | Form 4 |
| Jun 5, 2025 | MAXWELL MARTIN CDirector | Sale | 8,720 | $120.56 | $1.1M | Form 4 |
| Jun 4, 2025 | Spence Donald JDirector | Sale | 14,739 | $120.38 | $1.8M | Form 4 |
| May 1, 2025 | Dziedzic Joseph WPresident & CEO | Sale | 338,975 | $123.17 | $41.8M | Form 4 |
| Jul 31, 2024 | Hobby Jean M.Director | Sale | 11,960 | $119.66 | $1.4M | Form 4 |
| Jul 31, 2024 | MAXWELL MARTIN CDirector | Sale | 4,700 | $118.88 | $558.7K | Form 4 |
| Jul 30, 2024 | Harris John APresident, Glob Ops & Manu Tec | Sale | 3,400 | $123.80 | $420.9K | Form 4 |
| Jun 4, 2024 | Harris John APresident, Glob Ops & Manu Tec | Sale | 1,521 | $120.44 | $183.2K | Form 4 |
| May 24, 2024 | Hinrichs James F.Director | Sale | 9,603 | $122.44 | $1.2M | Form 4 |
| May 10, 2024 | Khales PaymanPresident & CEO | Sale | 8,712 | $113.84 | $991.8K | Form 4 |
| May 7, 2024 | Harris John APresident, Glob Ops & Manu Tec | Sale | 312 | $113.00 | $35.3K | Form 4 |
| May 7, 2024 | Senn AndrewPresident, Growth & Innovation | Sale | 5,000 | $113.14 | $565.7K | Form 4 |
All 31 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Tarheel Investors III L.P.SCHEDULE 13D, 1 filing Oct 13, 2026108
- Nomura HoldingsSCHEDULE 13G, 1 filing Aug 14, 2026109
- InvescoSCHEDULE 13G, 1 filing May 6, 2026110
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 2026111
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 2026112
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 2026113
- BlackRockSCHEDULE 13G/A, 5 filings Jan 28, 2022 to Jul 17, 2025114
- DIMENSIONAL FUND ADVISORS LPSCHEDULE 13G/A, 5 filings Feb 8, 2022 to Apr 15, 2025115
- FRANKLIN MUTUAL ADVISERS LLCSC 13G/A, 2 filings Jan 31, 2023 to Jan 30, 2024116
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Joseph W. Dziedzic | $1.2M | $8.7M117 | |
| 2025 | Payman Khales | 56 | $637.0K | $3.2M117 |
| 2025 | Diron Smith | $499.1K | $2.6M117 | |
| 2025 | Andrew Senn | $434.1K | $1.7M117 | |
| 2025 | Jim Stephens | $504.4K | $1.7M117 | |
| 2025 | Lindsay K. Blackwood | $365.4K | $1.6M117 | |
| 2024 | Former President and CEO | $1.2M | $8.7M117 | |
| 2024 | Executive VicePresident and Chief Financial Officer | $440.0K | $2.5M117 | |
| 2024 | President and CEO | $550.0K | $1.9M117 | |
| 2024 | PresidentCardiac Rhythm Management & Neuromodulation | $461.8K | $1.6M117 | |
| 2023 | Former President and CEO | $1.2M | $8.7M117 | |
| 2023 | President and CEO | $528.8K | $4.0M117 | |
| 2023 | Executive VicePresident and Chief Financial Officer | $345.9K | $1.3M117 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 5,353,741 | $500.3M | 0.0% | +47,900 |
| Invesco Ltd. | 2,247,031 | $210.0M | 0.0% | +277,898 |
| Vanguard Portfolio Management LLC | 2,040,469 | $190.7M | 0.0% | −6,497 |
| Dimensional Fund Advisors LP | 1,627,784 | $152.1M | 0.0% | +143,388 |
| Nomura Holdings Inc | 1,554,450 | $145.3M | 0.6% | +1,106,089 |
| Vanguard Capital Management LLC | 1,531,843 | $143.2M | 0.0% | −5,444 |
| State Street Corp | 1,413,174 | $132.0M | 0.0% | +14,888 |
| Morgan Stanley | 1,345,748 | $125.8M | 0.0% | −193,535 |
| Irenic Capital Management LP | 1,264,259 | $118.1M | 8.5% | +596 |
| Earnest Partners LLC | 1,008,519 | $94.2M | 0.3% | −32,629 |
| Hudson Bay Capital Management LP | 1,000,000 | $93.5M | 0.5% | No change |
| Citadel Advisors LLC | 965,753 | $90.2M | 0.1% | +272,696 |
| Geode Capital Management, LLC | 879,457 | $82.2M | 0.0% | +45,095 |
| Alliancebernstein L.P. | 913,117 | $80.4M | 0.0% | −390,267 |
| Massachusetts Financial Services Co /ma/ | 788,214 | $73.7M | 0.0% | −17,660 |
| Healthcare Of Ontario Pension Plan Trust Fund | 778,700 | $72.8M | 0.1% | −40,346 |
| Goldman Sachs Group Inc | 576,830 | $53.9M | 0.0% | +231,231 |
| Manufacturers Life Insurance Company, The | 544,942 | $50.9M | 0.0% | −53,584 |
| Brown Advisory Inc | 544,327 | $50.9M | 0.1% | New |
| Bank Of America Corp /de/ | 473,933 | $44.3M | 0.0% | −96,720 |
| Charles Schwab Investment Management Inc | 473,419 | $44.2M | 0.0% | +9,782 |
| Northern Trust Corp | 423,204 | $39.5M | 0.0% | +5,015 |
| CIBC Bancorp USA Inc. | 381,931 | $35.7M | 0.0% | −369,833 |
| William Blair Investment Management, LLC | 378,706 | $35.4M | 0.1% | +86,105 |
| Silvercrest Asset Management Group LLC | 371,484 | $34.7M | 0.2% | −29,285 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Integer is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARInteger Holdings Corp2
- CIK0001114483
- Employer ID (EIN)16-15310266
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsDecember 312
- Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address5830 Granite Parkway., Suite 1150, Plano, TX 750242
- Phone(214) 618-52432
- Shares outstanding33,992,048 as of Jul 30, 202613
- Public float$4.3B as of Jun 27, 20256
- AuditorDeloitte & Touche LLP, Williamsville, New York PCAOB ID 34; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceMay 22, 20002
- Filings1,803 in all: 4 (988), 8-K (286), SC 13G/A (99), 10-Q (78), 3 (69), SC 13G (41), 10-K (26), DEF 14A (26)2
All 45 form types
424B3 (24), 4/A (23), 144 (19), DEFA14A (18), SD (13), S-8 (11), UPLOAD (10), ARS (9), S-1/A (8), 8-K/A (7), CORRESP (6), SCHEDULE 13G (4), SCHEDULE 13G/A (4), 10-Q/A (3), PRE 14A (3), SC TO-T/A (3), 424B4 (2), 8-A12B (2), S-1 (2), S-3 (2), 10-K/A (1), 3/A (1), 5 (1), CERTNYS (1), D (1), DEFM14A (1), EFFECT (1), PREM14A (1), REGDEX/A (1), S-1MEF (1), S-3/A (1), S-3ASR (1), SC 13D (1), SC 13D/A (1), SC TO-C (1), SC TO-T (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Feb 23, 2026
Quarterly report (10-Q) Aug 4, 2026
Proxy statement (DEF 14A) Apr 6, 2026
Latest 8-K (8-K) Oct 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, Par Value $0.001 Per Share | ITGR | New York Stock Exchange |
From the cover page of the 10-K filed Feb 23, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks Integer names in Item 1A of its 10-K filed Feb 23, 2026: 38 risks under these headings, as written.6
- Operational Risks
- We depend heavily on a limited number of customers, and if we lose any of them or they significantly reduce their business with us, we would lose a substantial portion of our revenues.
- We are subject to pricing pressures from customers and contractual pricing constraints, which could harm our operating results and financial condition.
- We rely on third-party suppliers for raw materials, key products, subcomponents, and services. Unavailability of, or increased prices for, these materials, products, subcomponents, or services could adversely affect our results of operations and financial condition.
- If we are not able to match our manufacturing capacity with demand for our products, our financial results may suffer.
- Interruptions of our manufacturing operations could delay production and adversely affect our operations.
- We may not be able to attract, train and retain a sufficient number of qualified associates to maintain and grow our business.
- Quality problems with our products could result in warranty claims and additional costs, could harm our reputation and could erode our competitive advantage.
- Our operations are subject to cyber-attacks and other information technology disruptions that could have a material adverse effect on our business, results of operations and financial condition.
- Global climate change and related emphasis on environmental, social and governance (“ESG”) matters by various stakeholders could negatively affect our business or the price of our common stock.
- We are dependent upon our senior management team and key technical personnel and the loss of any of them could significantly harm us.
- Consolidation in the healthcare industry could result in greater competition and reduce our revenues and harm our business and our operating results.
The other 27 risks
- Strategic Risks
- If we are unable to successfully market our current or future products, our business will be harmed and our revenues and operating results will be adversely affected.
- We may face intense competition that could harm our business, including competitors, insourcing and the possibility of dual sourcing; and we may be unable to compete successfully against new entrants and established companies with greater resources.
- If we do not respond to changes in technology, our products may become obsolete or less competitive and we may experience a loss of customers and lower revenues.
- We intend to develop new products and expand into new geographic and product markets, which may not be successful and could harm our operating results.
- If we are not successful in making acquisitions to expand and develop our business, our operating results may suffer.
- Successful integration and anticipated benefits of acquisitions cannot be assured and integration matters could divert attention of management away from operations.
- Market, Financial and Indebtedness Risks
- Our operating results may fluctuate, which may make it difficult to forecast our future performance and may result in volatility in our common stock price and declines in the price of common stock could subject us to litigation.
- We cannot guarantee that we will repurchase our common stock pursuant to our share repurchase program or that our share repurchase program will enhance long-term stockholder value. Share repurchases could also increase the volatility of the price of our common stock and could diminish our cash reserves.
- Activist shareholders could negatively impact our business and cause disruptions.
- We have significant indebtedness that could adversely affect our operations, financial condition, and cash flows if we fail to meet certain financial covenants required by our debt agreements or if our access to capital markets is interrupted.
- Economic and credit market uncertainty could interrupt our access to capital markets, borrowings, or financial transactions to hedge certain risks, which could adversely affect our business prospects and financial condition.
- The conditional conversion features of the 2028 Convertible Notes and the 2030 Convertible Notes could adversely affect our financial condition and operating results.
- Certain provisions in the 2028 Convertible Notes, the indenture governing the 2028 Convertible Notes, the 2030 Convertible Notes and the indenture governing the 2030 Convertible Notes could delay or prevent an otherwise beneficial takeover or takeover attempt of us.
- Transactions relating to our 2028 Convertible Notes or the 2030 Convertible Notes may affect the market price of our common stock.
- We are subject to counterparty risk with respect to the capped call transactions for the 2028 Convertible Notes and the 2030 Convertible Notes.
- A significant portion of our sales and operations is currently generated from customers located outside of the U.S., and are subject to a variety of market and financial risks and costs that could adversely affect our profitability and operating results.
- We have a complex tax profile due to the global nature of our operations and may experience increases and variability in our quarterly and annual effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, business acquisitions, settlements with taxing authorities and changes in tax rates.
- We may never realize the full value of our intangible assets, which represent a significant portion of our total assets.
- Legal and Compliance Risks
- Regulatory issues resulting from product complaints, recalls or regulatory audits could harm our ability to produce and supply products or bring new products to market.
- If we become subject to product liability claims, our operating results and financial condition could suffer.
- If we are unable to protect our intellectual property and proprietary rights, our business could be harmed.
- We may be subject to intellectual property claims, which could be costly and time consuming and could divert our management’s attention from our business operations.
- A failure to comply with customer-driven policies and standards and third-party certification requirements or standards could adversely affect our business and reputation.
- Our failure to obtain licenses from third parties for new technologies or the loss of these licenses could impair our ability to design and manufacture new products and reduce our revenues.
- Our international operations expose us to legal and regulatory risks, which could adversely affect our business.
- The healthcare industry is highly regulated and subject to various political, economic and regulatory changes that could increase our compliance costs and force us to modify how we develop and price our products.
- Our business is indirectly subject to healthcare industry third-party coverage and reimbursement and cost containment measures that could result in reduced sales of our products.
Legal proceedings
For information regarding certain legal proceedings pending against us, see Note 14, “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements contained in Item 8, “Financial Statements and Supplementary Data,” of this report, which is incorporated herein by reference.
The opening of Item 3, Legal Proceedings.6
Links
- Websitewww.greatbatch.com1
- Websitewww.integer.net1
- WikidataQ30297996
- SEC EDGARCIK 1114483
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataInteger on Wikidata
- 2SEC EDGARInteger filings on SEC EDGAR
- 3Yahoo FinanceITGR quote
- 4SEC EDGARInteger filings on SEC EDGAR
- 5
- 6
- 7SEC EDGARInteger 10-K for fiscal 2025
- 8SEC EDGARInteger 10-K for fiscal 2019
- 9SEC EDGARInteger 10-K for fiscal 2020
- 10SEC EDGARInteger 10-K for fiscal 2021
- 11SEC EDGARInteger 10-K for fiscal 2022
- 12SEC EDGARInteger 10-Q for fiscal 2026
- 13SEC EDGARInteger 10-Q for fiscal 2026
- 14SEC EDGARInteger 10-K for fiscal 2019
- 15
- 16
- 17
- 18
- 19SEC EDGARAndrew Senn, President
- 20SEC EDGARCarter Houghton, President
- 21SEC EDGARPayman Khales, President
- 22SEC EDGARJennifer M. Bolt, President
- 23SEC EDGARJeremy Friedman, President
- 24SEC EDGARJose Antonio Gonzalez, President
- 25SEC EDGARMauricio Arellano, President
- 26SEC EDGARDiron Smith, Chief financial officer
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55SEC EDGARJohn Ayliffe, VP Europe
- 56SEC EDGARPatrick Berdoz, Sr. VP Orthopedics
- 57SEC EDGARTimothy G. McEvoy, Vice President
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65SEC EDGARAaron Kapito, Board member
- 66SEC EDGARMichael J. Coyle, Board member
- 67SEC EDGARAlvin Tyrone Jeffers, Board member
- 68SEC EDGARCheryl C. Capps, Board member
- 69SEC EDGARSheila Antrum, Board member
- 70SEC EDGARJames F. Hinrichs, Board member
- 71SEC EDGARMarcia A. Dall, Board member
- 72SEC EDGARFilippo Passerini, Board member
- 73SEC EDGARJean M. Hobby, Board member
- 74SEC EDGARMartin C. Maxwell, Board member
- 75SEC EDGARJoseph W. Dziedzic, Board member
- 76SEC EDGARRudy A. Mazzocchi, Board member
- 77SEC EDGARAnthony P. Bihl Iii., Board member
- 78SEC EDGARHelena S. Wisniewski, Board member
- 79SEC EDGARMichael Dinkins, Board member
- 80SEC EDGARKevin C. Melia, Board member
- 81SEC EDGARJohn P. Wareham, Board member
- 82SEC EDGARPamela G. Bailey, Board member
- 83SEC EDGARPeter H. Soderberg, Board member
- 84SEC EDGARWilliam B. Summers Jr., Board member
- 85SEC EDGARBill R. Sanford, Board member
- 86SEC EDGARJoseph A. Miller, Board member
- 87SEC EDGARThomas S. Summer, Board member
- 88SEC EDGAREdward F. Voboril, Board member
- 89SEC EDGARElizabeth Giddens, General counsel
- 90SEC EDGAROther events
- 91SEC EDGAROther events
- 92SEC EDGAROther events
- 93
- 94SEC EDGARResults of operations
- 95SEC EDGARRegulation FD disclosure
- 96SEC EDGARExecutive or director change
- 97
- 98
- 99
- 100
- 101SEC EDGAROther events
- 102NasdaqNasdaq calendar
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110SEC EDGARInvesco SCHEDULE 13G on Integer
- 111
- 112
- 113
- 114SEC EDGARBlackRock SCHEDULE 13G/A on Integer
- 115
- 116
- 117